Literature DB >> 15708075

Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin.

Apostolos Apostolidis1, Ciaran M Brady, Yiangos Yiangou, John Davis, Clare J Fowler, Praveen Anand.   

Abstract

OBJECTIVES: To study TRPV1 immunoreactivity in the urothelium of patients with neurogenic detrusor overactivity (NDO) before and after treatment with resiniferatoxin (RTX) and controls. Functional capsaicin TRPV1 receptors have been demonstrated in urothelial cells of rodent urinary bladder, and TRPV1-knockout mice exhibit diminished nitric oxide and stretch-evoked adenosine triphosphate release from urothelial cells. In patients with NDO, TRPV1 suburothelial nerve density is increased, which is reversed by successful treatment with intravesical RTX. However, the role of urothelial TRPV1 in human bladder disorders is unknown.
METHODS: Flexible cystoscopic bladder biopsies were obtained from 14 patients with NDO before and after treatment with RTX and from 8 control patients. Using a specific antibody for immunostaining, TRPV1 immunoreactivity in the urothelium was quantified by image analysis.
RESULTS: TRPV1 immunoreactivity was observed in basal and apical urothelial cells. Basal cell layer TRPV1 immunoreactivity was significantly increased in NDO compared with control bladders (P = 0.003). In 5 patients who responded clinically to RTX, basal cell layer and total urothelial TRPV1 immunoreactivity decreased significantly after treatment (P = 0.032 and P = 0.016, respectively). The decreases in the basal cell layer TRPV1 immunoreactivity after RTX were comparable to the decreases in suburothelial TRPV1 nerve fibers in the biopsies previously studied from the same patients.
CONCLUSIONS: Increased urothelial TRPV1 in patients with NDO may play a role in the pathophysiology, in concert with increased TRPV1 nerve fibers. Although it is not known whether similar pathogenic mechanisms are involved in the increase of urothelial and neuronal TRPV1, both may be targeted by successful RTX therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708075     DOI: 10.1016/j.urology.2004.10.007

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  58 in total

Review 1.  From urgency to frequency: facts and controversies of TRPs in the lower urinary tract.

Authors:  Roman Skryma; Natalia Prevarskaya; Dimitra Gkika; Yaroslav Shuba
Journal:  Nat Rev Urol       Date:  2011-10-04       Impact factor: 14.432

Review 2.  Bladder afferent signaling: recent findings.

Authors:  Anthony Kanai; Karl-Erik Andersson
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

Review 3.  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

Authors:  António Avelino; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-24       Impact factor: 3.000

Review 4.  Integrated control of lower urinary tract--clinical perspective.

Authors:  Clare J Fowler
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 5.  Defining protein expression in the urothelium: a problem of more than transitional interest.

Authors:  Weiqun Yu; Warren G Hill
Journal:  Am J Physiol Renal Physiol       Date:  2011-08-31

Review 6.  Changes in afferent activity after spinal cord injury.

Authors:  William C de Groat; Naoki Yoshimura
Journal:  Neurourol Urodyn       Date:  2010       Impact factor: 2.696

Review 7.  TRPV1: on the road to pain relief.

Authors:  Andrés Jara-Oseguera; Sidney A Simon; Tamara Rosenbaum
Journal:  Curr Mol Pharmacol       Date:  2008-11       Impact factor: 3.339

8.  Beyond neurons: Involvement of urothelial and glial cells in bladder function.

Authors:  Lori A Birder; Amanda S Wolf-Johnston; Manjul K Chib; Charles A Buffington; James R Roppolo; Ann T Hanna-Mitchell
Journal:  Neurourol Urodyn       Date:  2010       Impact factor: 2.696

9.  Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1.

Authors:  Yi-Chen Lee; Shui-Chin Lu; Yu-Lin Hsieh
Journal:  J Vis Exp       Date:  2018-02-13       Impact factor: 1.355

10.  Selective targeting of TRPV1 expressing sensory nerve terminals in the spinal cord for long lasting analgesia.

Authors:  Joseph A Jeffry; Shuang-Quan Yu; Parul Sikand; Arti Parihar; M Steven Evans; Louis S Premkumar
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.